Literature DB >> 15259648

Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions.

S K Das1, M M Miften, S Zhou, M Bell, M T Munley, C S Whiddon, O Craciunescu, A H Baydush, T Wong, J G Rosenman, M W Dewhirst, L B Marks.   

Abstract

The information provided by functional images may be used to guide radiotherapy planning by identifying regions that require higher radiation dose. In this work we investigate the dosimetric feasibility of delivering dose to lung tumors in proportion to the fluorine-18-fluorodeoxyglucose activity distribution from positron emission tomography (FDG-PET). The rationale for delivering dose in proportion to the tumor FDG-PET activity distribution is based on studies showing that FDG uptake is correlated to tumor cell proliferation rate, which is shown to imply that this dose delivery strategy is theoretically capable of providing the same duration of local control at all voxels in tumor. Target dose delivery was constrained by single photon emission computed tomography (SPECT) maps of normal lung perfusion, which restricted irradiation of highly perfused lung and imposed dose-function constraints. Dose-volume constraints were imposed on all other critical structures. All dose-volume/function constraints were considered to be soft, i.e., critical structure doses corresponding to volume/function constraint levels were minimized while satisfying the target prescription, thus permitting critical structure doses to minimally exceed dose constraint levels. An intensity modulation optimization methodology was developed to deliver this radiation, and applied to two lung cancer patients. Dosimetric feasibility was assessed by comparing spatially normalized dose-volume histograms from the nonuniform dose prescription (FDG-PET proportional) to those from a uniform dose prescription with equivalent tumor integral dose. In both patients, the optimization was capable of delivering the nonuniform target prescription with the same ease as the uniform target prescription, despite SPECT restrictions that effectively diverted dose from high to low perfused normal lung. In one patient, both prescriptions incurred similar critical structure dosages, below dose-volume/function limits. However, in the other patient, critical structure dosage from the nonuniform dose prescription exceeded dose-volume/function limits, and greatly exceeded that from the uniform dose prescription. Strict compliance to dose-volume/ function limits would entail reducing dose proportionality to the FDG-PET activity distribution, thereby theoretically reducing the duration of local control. Thus, even though it appears feasible to tailor lung tumor dose to the FDG-PET activity distribution, despite SPECT restrictions, strict adherence to dose-volume/function limits could compromise the effectiveness of functional image guided radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259648     DOI: 10.1118/1.1750991

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  23 in total

1.  Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients.

Authors:  Stephen R Bowen; Jatinder Saini; Tobias R Chapman; Robert S Miyaoka; Paul E Kinahan; George A Sandison; Tony Wong; Hubert J Vesselle; Matthew J Nyflot; Smith Apisarnthanarax
Journal:  Radiother Oncol       Date:  2015-04-28       Impact factor: 6.280

2.  Comparison of intensity modulated x-ray therapy and intensity modulated proton therapy for selective subvolume boosting: a phantom study.

Authors:  R T Flynn; D L Barbee; T R Mackie; R Jeraj
Journal:  Phys Med Biol       Date:  2007-10-01       Impact factor: 3.609

3.  Reproducibility of four-dimensional computed tomography-based lung ventilation imaging.

Authors:  Tokihiro Yamamoto; Sven Kabus; Jens von Berg; Cristian Lorenz; Melody P Chung; Julian C Hong; Billy W Loo; Paul J Keall
Journal:  Acad Radiol       Date:  2012-09-10       Impact factor: 3.173

Review 4.  Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription.

Authors:  Søren M Bentzen; Vincent Gregoire
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

Review 5.  Functional and molecular image guidance in radiotherapy treatment planning optimization.

Authors:  Shiva K Das; Randall K Ten Haken
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

Review 6.  (18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications.

Authors:  Gianpiero Manca; Eleonora Vanzi; Domenico Rubello; Francesco Giammarile; Gaia Grassetto; Ka Kit Wong; Alan C Perkins; Patrick M Colletti; Duccio Volterrani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-19       Impact factor: 9.236

7.  A segmentation framework towards automatic generation of boost subvolumes for FDG-PET tumors: a digital phantom study.

Authors:  Fei Yang; Perry W Grigsby
Journal:  Eur J Radiol       Date:  2012-07-27       Impact factor: 3.528

8.  On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function.

Authors:  Stephen R Bowen; Ryan T Flynn; Søren M Bentzen; Robert Jeraj
Journal:  Phys Med Biol       Date:  2009-02-13       Impact factor: 3.609

9.  A registration based approach for 4D cardiac micro-CT using combined prospective and retrospective gating.

Authors:  Cristian T Badea; Eduard Schreibmann; Tim Fox
Journal:  Med Phys       Date:  2008-04       Impact factor: 4.071

10.  Feasibility of image registration and intensity-modulated radiotherapy planning with hyperpolarized helium-3 magnetic resonance imaging for non-small-cell lung cancer.

Authors:  Rob H Ireland; Chris M Bragg; Mark McJury; Neil Woodhouse; Stan Fichele; Edwin J R van Beek; Jim M Wild; Matthew Q Hatton
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.